ECSP11011009A - Forma de dosificación oral de liberación prolongada de acetaminofeno/tramadol - Google Patents

Forma de dosificación oral de liberación prolongada de acetaminofeno/tramadol

Info

Publication number
ECSP11011009A
ECSP11011009A EC2011011009A ECSP11011009A ECSP11011009A EC SP11011009 A ECSP11011009 A EC SP11011009A EC 2011011009 A EC2011011009 A EC 2011011009A EC SP11011009 A ECSP11011009 A EC SP11011009A EC SP11011009 A ECSP11011009 A EC SP11011009A
Authority
EC
Ecuador
Prior art keywords
tramadol
dosage form
prolonged
acetaminofen
oral dosage
Prior art date
Application number
EC2011011009A
Other languages
English (en)
Inventor
wei guo Dai
Liang Chang Dong
Tae Hong Choi
Sung Joo Hwang
Jae Hyun Kim
Dong Ho Lee
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41514164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011009(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of ECSP11011009A publication Critical patent/ECSP11011009A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una forma de dosificación de liberación prolongada de administración oral de acetaminofeno y tramadol. La forma de dosificación incluye una composición de acetaminofeno junto con un complejo de tramadol formado con un polímero aniónico. El complejo de tramadol proporciona la liberación sostenida de tramadol para un perfil de liberación sincronizado (coordinado) de acetaminofeno y tramadol.
EC2011011009A 2008-10-27 2011-04-27 Forma de dosificación oral de liberación prolongada de acetaminofeno/tramadol ECSP11011009A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10861808P 2008-10-27 2008-10-27

Publications (1)

Publication Number Publication Date
ECSP11011009A true ECSP11011009A (es) 2011-06-30

Family

ID=41514164

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011009A ECSP11011009A (es) 2008-10-27 2011-04-27 Forma de dosificación oral de liberación prolongada de acetaminofeno/tramadol

Country Status (25)

Country Link
US (1) US20100104638A1 (es)
EP (1) EP2362768B1 (es)
JP (1) JP5713911B2 (es)
KR (3) KR20110036858A (es)
CN (2) CN107028908A (es)
AU (1) AU2009320181B2 (es)
BR (1) BRPI0920082A2 (es)
CA (1) CA2741751C (es)
CL (1) CL2011000935A1 (es)
CO (1) CO6331423A2 (es)
CR (1) CR20110287A (es)
EA (1) EA023149B1 (es)
EC (1) ECSP11011009A (es)
ES (1) ES2582779T3 (es)
HN (1) HN2011001184A (es)
IL (1) IL212453A (es)
MX (1) MX339867B (es)
MY (1) MY161550A (es)
NI (1) NI201100079A (es)
NZ (1) NZ592325A (es)
PE (1) PE20110855A1 (es)
TW (1) TWI561257B (es)
UA (1) UA102706C2 (es)
WO (1) WO2010062524A1 (es)
ZA (1) ZA201103880B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
BRPI0912014A2 (pt) 2008-05-09 2019-03-06 Grünenthal GmbH processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob uso de uma etapa de congelamento por atomização
RU2015138422A (ru) 2009-07-22 2018-12-25 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
CN102573805A (zh) 2009-07-22 2012-07-11 格吕伦塔尔有限公司 热熔挤出的控制释放剂型
BR112013005234A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo um polímero aniônico.
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt
AU2012253834B2 (en) * 2011-05-06 2016-06-16 Glaxosmithkline Consumer Healthcare (Uk) Ip Limited Sustained release paracetamol formulations
US10702485B2 (en) * 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
RS56527B1 (sr) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
PE20141638A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US20130303632A1 (en) * 2012-05-10 2013-11-14 Fmc Corporation Controlled release solid dose form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
DE102013009114A1 (de) 2013-05-29 2014-12-04 Franz Gerstheimer Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
WO2015044952A2 (en) * 2013-09-30 2015-04-02 Athena Drug Delivery Solutions Pvt Ltd. Tramadol hydrochloride and paracetamol orally disintegrating composition and process for preparing the same
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
WO2015091352A1 (en) 2013-12-16 2015-06-25 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile manufactured by co-extrusion
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
JP2018517676A (ja) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時放出および溶媒抽出に対する耐性を有する改変防止製剤
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
GB2567493B (en) 2017-10-13 2019-12-18 Altus Formulation Inc Starch-based release modifying excipients and pharmaceutical compositions derived therefrom
ES2913642T3 (es) * 2017-10-13 2022-06-03 Altus Formulation Inc Excipientes modificadores de la liberación a base de almidón y composiciones farmacéuticas derivadas de los mismos
US11000488B2 (en) 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol
KR20240027436A (ko) * 2022-08-23 2024-03-04 대원제약주식회사 펠루비프로펜 및 트라마돌의 이온결합 화합물, 이를 포함하는 조성물, 및 이의 제조 방법
KR20240158668A (ko) * 2023-04-27 2024-11-05 대원제약주식회사 펠루비프로펜 및 트라마돌을 포함하는 진통용 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58206751A (ja) * 1982-05-26 1983-12-02 日石三菱株式会社 創傷被覆材
HU219332B (hu) 1991-09-06 2001-03-28 Mcneilab Inc Transz-(+)-2-[(dimetil-amino)-metil]-1-(3-metoxi-fenil)-ciklohexanolt és acetaminofent tartalmazó szinergetikus gyógyszerkészítmények
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
ATE386509T1 (de) 2002-09-21 2008-03-15 Shuyi Zhang Formulierung von acetaminophen und tramadol mit verzögerter freisetzung
WO2004037222A2 (en) * 2002-10-25 2004-05-06 Labopharm Inc. Sustained-release tramadol formulations with 24-hour efficacy
WO2006053012A2 (en) * 2004-11-10 2006-05-18 Trinity Laboratories, Inc. Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria
CN101257894A (zh) * 2005-07-07 2008-09-03 法纳姆公司 高水溶性药物的缓释药物组合物
RU2008113439A (ru) * 2005-09-09 2009-10-20 Лабофарм Инк. (CA) Композиции с замедленным высвобождением лекарственного средства
CN1785167A (zh) * 2005-10-08 2006-06-14 王鸣 一种非麻醉性镇痛剂的复方缓释制剂的制备方法
DE102006056458A1 (de) * 2006-11-28 2008-05-29 Grünenthal GmbH Arzneimittelzubereitung von Tramadol und Acetaminophen
EA201070158A1 (ru) * 2007-07-18 2010-08-30 Янссен Фармацевтика Н.В. Сульфонамиды в качестве trpm8 модуляторов
WO2009076764A1 (en) * 2007-12-17 2009-06-25 Labopharm Inc. Misuse preventative, controlled release formulation
US8377453B2 (en) * 2008-03-11 2013-02-19 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic

Also Published As

Publication number Publication date
US20100104638A1 (en) 2010-04-29
CL2011000935A1 (es) 2011-10-21
KR20130137720A (ko) 2013-12-17
EP2362768B1 (en) 2016-04-20
HK1162915A1 (zh) 2012-09-07
EA201170616A1 (ru) 2011-12-30
MX339867B (es) 2016-06-14
KR101631140B1 (ko) 2016-06-20
CN102264355A (zh) 2011-11-30
JP5713911B2 (ja) 2015-05-07
AU2009320181A1 (en) 2010-06-03
CO6331423A2 (es) 2011-10-20
CA2741751C (en) 2017-05-09
ZA201103880B (en) 2012-10-31
TWI561257B (en) 2016-12-11
WO2010062524A1 (en) 2010-06-03
KR20110036858A (ko) 2011-04-11
EP2362768A1 (en) 2011-09-07
AU2009320181B2 (en) 2015-08-27
KR20110119845A (ko) 2011-11-02
TW201028180A (en) 2010-08-01
MX2011004403A (es) 2011-05-25
NI201100079A (es) 2011-10-21
CN107028908A (zh) 2017-08-11
CR20110287A (es) 2011-11-10
BRPI0920082A2 (pt) 2019-09-24
UA102706C2 (ru) 2013-08-12
ES2582779T3 (es) 2016-09-15
IL212453A (en) 2017-03-30
HN2011001184A (es) 2014-09-01
JP2012506907A (ja) 2012-03-22
NZ592325A (en) 2012-09-28
CA2741751A1 (en) 2010-06-03
IL212453A0 (en) 2011-06-30
PE20110855A1 (es) 2011-12-05
EA023149B1 (ru) 2016-04-29
MY161550A (en) 2017-04-28

Similar Documents

Publication Publication Date Title
CO6331423A2 (es) Forma de dosificacion oral de liberacion prolongada de acetaminofeno/tramadol.
AR114143A2 (es) Formulaciones de comprimidos revestidos
AR088232A1 (es) Composiciones farmaceuticas
UY31698A (es) Preparacion solida de desintegracion oral
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
EA201390804A1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
ECSP10010295A (es) Formulacion de anticuerpo
CL2015000544A1 (es) Una composicion farmaceutica que comprende regorafenib y al menos un excipiente farmaceuticamente aceptable, en el que la composicion esta recubierta por un recubrimiento que comprende un polimero basado en alcohol polivinilico; y su procedimiento de preparacion.
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
CL2018000811A1 (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral.
AR082493A1 (es) Formulaciones a base de nalbufina, y sus utilizaciones
MY191875A (en) Solid dosage form
CY1114190T1 (el) Νεα μορφη χορηγησης της ρασεκαδοτριλης
CL2010000281A1 (es) Formulacion oral en forma de tableta de 9-[(2,2-dimetil-propilamino)-metil]-minociclina; metodo de preparacion; formulacion inyectable del mismo; utiles en el tratamiento de una infeccion.
EA200900958A1 (ru) Препарат невирапина пролонгированного высвобождения
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
CL2008003006A1 (es) Uso de ester metilico del acido (-)-(3ar,4s,7ar)-4-hidroxi-4-m-toliletinil-octahidro-indol-1-carboxilico en base libre o en forma de sal para el tratamiento, prevencion o retraso de la progresion de la disquinesia de parkinson asociada a l-dopa; uso de la composicion farmaceutica; uso de una composicion que ademas comprende l-dopa.
AR082215A1 (es) Composicion farmaceutica agradable al paladar
AR092356A1 (es) Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion
CY1113641T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει aleglitazar
DOP2015000089A (es) Composición de difenidol de liberación prolongada
DE602008002371D1 (de) Pharmazeutische zusammensetzung mit candesartan-cilexetil
MX2013012918A (es) Formulaciones de liberacion sostenida de paracetamol.
ITFI20080016A1 (it) Formulazioni farmaceutiche orali contenenti gliclazide.